The structural logic of MUC1 explains both its normal function and its malignant potential. The MUC1 gene, located on chromosome 1q21-24, encodes a single polypeptide of 120 to 225 kilodaltons that balloons to 250 to 500 kilodalts after glycosylation. Its extracellular region contains between 20 and more than 100 tandem repeats of a 20-amino-acid sequence, each repeat carrying five O-glycosylation sites, producing a glycocalyx that extends hundreds of nanometers beyond the cell surface. Critically, the protein undergoes autoproteolysis within its SEA domain, cleaving at a GSVVV motif into two subunits that remain associated as a non-covalent heterodimer: MUC1-N, the sheddable, sugar-laden protective arm, and MUC1-C, a compact transmembrane unit with a 58-amino-acid extracellular domain, a 28-amino-acid membrane anchor, and a 72-amino-acid cytoplasmic tail that functions as the molecule’s oncogenic brain. In normal epithelia, the complex sits strictly at the apical membrane; in tumors, it spreads across the entire cell surface and into the cytoplasm, its O-glycans truncated into tumor-associated forms such as Tn, sTn, TF, and sTF.

MUC1-C is where the real molecular action happens. Its extracellular domain carries an NLT motif whose N-glycans recruit galectin-3, which in turn bridges MUC1-C to EGFR and other receptor tyrosine kinases at the membrane. Its cytoplasmic tail bristles with 12 documented and putative phosphorylation sites that serve as substrates for EGFR, Src-family kinases, ABL, GSK3β, and ZAP70, creating docking platforms for effectors such as PI3K, SRC, and GRB2. A CQC motif near the membrane, activated by reactive oxygen species, drives MUC1-C oligomerization and directs the protein to the nucleus via importin-β and to mitochondria via HSP70/90 chaperones, where it blocks the intrinsic apoptotic pathway. In the nucleus, MUC1-C binds β-catenin and TCF4 to occupy the CCND1 promoter, recruits p300 to acetylate histone H3K27, and interacts directly with p53, IKKα, IKKβ, and RelA, placing it at the command posts of the Wnt, p53, and NF-κB pathways simultaneously.

Two auto-inductive feedback loops give this signaling web its self-sustaining, pathological persistence. MUC1-C binds JAK1 and STAT3 directly, promoting STAT3 phosphorylation; activated STAT3 then binds the MUC1 promoter, cranking out more MUC1-C in a loop that is transient during normal inflammatory responses but constitutively locked on in carcinomas. A parallel loop operates with NF-κB, which MUC1-C activates both by stimulating the IKK complex and by physically blocking NF-κB’s inhibitor IκBα. Beyond these canonical circuits, the review highlights MUC1-C’s emerging role as an epigenetic master regulator: the protein induces the Yamanaka pluripotency factors OCT4, SOX2, KLF4, and MYC, binds the Polycomb marks H2A K119 ubiquitylation and H3K27 methylation, and reshapes chromatin accessibility at JUN/AP-1-regulated enhancers, thereby enforcing the lineage plasticity and stem-like state that make cancer cells so hard to eradicate.

The downstream consequences for anti-tumor immunity are stark. MUC1-C’s cytoplasmic tail sustains a JAK1-STAT1-IRF1 transcriptional axis that upregulates IDO1 and COX2/PTGES, depleting tryptophan, accumulating kynurenine, and generating prostaglandin E2, together halting CD8-positive T-cell cycling and pushing regulatory T-cell differentiation. MUC1-C also delivers mutant p53 and β-catenin to the CTGF promoter, unleashing connective tissue growth factor that recruits cancer-associated fibroblasts and deposits a physical collagen barrier. Analyses of TCGA, METABRIC, and single-cell datasets consistently show that MUC1-high tumors are depleted of cytotoxic T cells, Th1 helpers, B cells, and M1 macrophages while enriched in Tregs, myeloid-derived suppressor cells, and M2-polarized tumor-associated macrophages. Even at the glycan level, sTn-decorated MUC1 engages Siglec-9 on myeloid cells to trigger a calcium-MEK-ERK program that completes macrophage polarization and renders tumors refractory to PD-1 blockade, effectively converting an immunological hotbed into what the authors describe as an ice cave.

Disease-specific evidence reinforces the breadth of this mechanism. In breast cancer, high MUC1 mRNA predicts reduced overall, disease-free, and recurrence-free survival; MUC1-C interacts with estrogen receptor alpha to drive tamoxifen resistance, forms a self-sustaining loop with TWIST1 that underlies paclitaxel resistance, and cooperates with STAT1 in roughly 15 percent of primary breast tumors, a co-expression pattern linked to poor outcomes. In non-small cell lung cancer, MUC1-C drives acquired resistance to osimertinib by sustaining ERK and AKT signaling through EGFR/MET heterodimerization, occupies the CD274 promoter to induce PD-L1, and represses immune genes such as TLR9 and IFN-γ through ZEB1. In pancreatic ductal adenocarcinoma, where MUC1 is overexpressed in more than 60 percent of cases, the protein stabilizes HIF-1α, accelerates glycolysis and pyrimidine biosynthesis, and accumulates endogenous dCTP that directly antagonizes gemcitabine, while also suppressing BRCA1 and blunting radiosensitivity.

The oncogenic reach extends into blood cancers and chronic inflammatory disease. MUC1 is overexpressed specifically in acute myeloid leukemia stem cells, where it stabilizes both wild-type and mutant FLT3 receptors and activates the AKT/ERK/STAT5 axis; the peptide inhibitor GO-203 selectively eliminates these stem cells while sparing normal hematopoiesis. In chronic myeloid leukemia, MUC1 physically stabilizes the Bcr-Abl fusion protein and maintains imatinib resistance, while in multiple myeloma, aberrantly glycosylated MUC1 appears on 73 percent of malignant plasma cells and drives the WNT/β-catenin-TCF4-MYC survival program alongside redox balance maintained with TIGAR. Outside oncology, loss of MUC1 in chronic obstructive pulmonary disease correlates with steroid resistance, aberrant MUC1 glycosylation in ulcerative colitis promotes colitis-associated colorectal cancer, and frameshift mutations in the VNTR region cause autosomal dominant tubulointerstitial kidney disease through endoplasmic reticulum stress.

Therapeutically, the field has learned hard lessons but is now fielding a far more sophisticated arsenal. Only two MUC1-targeted drugs have reached phase III trials, the liposomal peptide vaccine Tecemotide and the poxviral vector TG4010, and both failed to improve survival, a result attributed in part to MUC1’s poor intrinsic immunogenicity and the redundancy of the pathways it controls. The current generation of approaches is more precise: monoclonal antibodies such as DMB5F3 against the SEA domain and GGSK-1/30, whose zirconium-89-labeled form achieved over 50 percent injected dose per gram tumor uptake with 96.5 percent diagnostic specificity in PET imaging; antibody-drug conjugates including 3D1-MMAE, which eradicated MUC1-positive lung and breast tumors in transgenic mice without toxicity; CAR-T cells engineered against the tumor-specific Tn-glycoform of MUC1, which spare normal epithelium; armored allogeneic CAR constructs with PD1 and TGFBR2 knockout and IL-12 insertion; oncolytic adenoviruses encoding MUC1-CD3 bispecific T-cell engagers; and RNA interference delivered by MUC1-aptamer-tethered nanoparticles.

The review’s authors are candid about the remaining obstacles. Because MUC1-C sits at the hub of so many compensatory networks, single-agent inhibition invites bypass signaling through AXL, MET, or downstream PI3K and MEK pathways, and chronic blockade can push cells toward stem-like or neuroendocrine phenotypes through epigenetic remodeling. The most promising path, they argue, is rational combination and sequencing: pairing MUC1-C inhibitors with PI3K/AKT/mTOR blockade, PD-1 antibodies, or epigenetic drugs such as decitabine, or using MUC1-C inhibition as a priming step to reverse epithelial-mesenchymal transition before conventional chemotherapy or checkpoint inhibitors. Preclinical combination studies already show dramatic gains, with a MUC1-MBP vaccine plus anti-PD-1 raising tumor clearance in mice from 20 to 80 percent. With nanodelivery systems, cell-carrier platforms, and MUC1-triggered smart materials now entering the design space, the molecule once dismissed after two failed phase III trials is being repositioned as what may become one of oncology’s most consequential pan-cancer targets, provided that mechanistic depth and rigorous clinical validation keep pace with the enthusiasm.

Subject of Research: The role of the MUC1 mucin, particularly its MUC1-C subunit, in oncogenic signaling, immune evasion, and targeted cancer therapy development

Article Title: MUC1 in cancer

Article References: Qian, K., Zhang, Y., Zhou, Q., Zhou, J., Wu, X., Zhu, J., Pan, Y., Wu, Z., Li, S., Lin, Y., Lyu, F., Chen, S., & Sun, H. (2026). MUC1 in cancer. Holistic Integrative Oncology, 5(1), Article 32. https://doi.org/10.1007/s44178-026-00257-w

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00257-w

Keywords: MUC1, MUC1-C, cancer biology, oncogenic signaling, immune evasion, immunotherapy, CAR-T cells, antibody-drug conjugates, cancer vaccines, drug resistance, epigenetic reprogramming, tumor microenvironment